Hadasit Bio-Holdings Ltd. ("HBL") was founded and floated on the Tel Aviv Stock Exchange (TASE : HDST ) in order to allow public participation in the highly promising field of biotechnology.
It serves as a precedent in biotech financing - for the first time, public investment is allowed to participate in a holding entity including companies based on IP generated by Israel’s foremost medical research center – Hadassah University Hospital ("HU").
In addition to the public holdings (47%) – including major Israeli institutional investors, HBL is held by Hadasit (www.hadasit.co.il) (41%). The traded stock, as a unique investment vehicle, provides investment exposure to a select cluster of 9 biotech companies - all based on inventions developed and owned by HU.
HBL is a publicly traded subsidiary of Hadasit Ltd. – the technology transfer company of the Hadassah University Hospital in Jerusalem, Israel. Hadasit was established for the purpose of promoting and commercializing the intellectual property (IP) and R&D capabilities generated by Hadassah, aimed at finding solutions to problems faced by modern medicine. | 
